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Summary To investigate the underlying mechanisms of carcinogenesis, we have developed a technique to
determine the frequency ofgenetic changes in prostatic carcinoma tissue. We have demonstrated that at a ratio
of between 1:4 and 1:9 mutant-normal alleles, the signal from a mutant TP53 allele is not apparent after
polymerase chain reaction (PCR) amplification and further direct sequencing or single-strand conformation
polymorphism (SSCP) analysis. To bypass this problem, which is inherent in the heterogeneity of the prostate
tissue and of the tumour, we selected areas of graded prostate tumours (Gleason score) from cryosectioned
preparations, and microdissected these cells (20-100 cells). After anionic resin removal of proteins, PCR
amplification of TP53 gene exons 5/6 and SSCP analysis, an abnormal SSCP band shift was observed in
suspected tumour cells, compared with microdissected stromal cells used as an internal control, while (1) a
crude preparation of tissue DNA carrying the tumour did not show any abnormality and (2) immunostaining
by a set of monoclonal antibodies against TP53 protein remained negative. Nucleotide sequence analysis ofthe
different bands confirmed the presence of a mutation in the TP53 gene exon 6 position 13 336 in an abnormal
band for one specimen, while no mutation was detected in the normal SSCP band. By targeting recognised
tumour cells we can find DNA mutations which are undetectable using the standard technique of whole-tissue
DNA extraction, particularly in a heterogeneous tumour such as carcinoma of the prostate.
Keywords: prostate cancer; microdissection; mutation analysis; p53
Prostatic carcinoma (CaP) is a major cause of male cancer
mortality worldwide, and together with benign prostatic
hyperplasia (BPH) represents a common cause of discomfort
in elderly men. These two pathologies are characterised by a
high degree of tissue heterogeneity. The ratio of prostatic
cancer cells to normal glandular or stromal cells varies widely
between biopsies. A morphometric analysis of 50 patients
with prostatic carcinoma revealed the presence of cancer cells
in 23%, stromal tissue in 72% and normal or BPH glandular
cells in 4% of all biopsy specimens examined (Bartsch et al.,
1989). Histological grading, tumour size, malignancy and
serum prostate-specific antigen (PSA) levels are currently the
most reliable tools for prostate cancer diagnosis.
To determine the prognosis of a particular tumour,
molecular markers, such as gene mutations associated with
the cancer progression, probably offer the most exciting pros-
pect in the field of cancer research (Fearon and Vogelstein,
1990). The ability to analyse these markers depends not only
upon optimised procedures to detect a mutation, but also on
the proportion of the sample which contains this mutation.
Prostate cancer is characterised by a remarkably low fre-
quency of alterations in genes known to be associated with
other malignancies such as ras, myc, erbB-2, TP53, RB
(Bishop, 1991). Given the heterogeneity of biopsies, these low
frequencies could stem from a failure to detect mutations
actually present within prostatic carcinoma. So far, no
oncogenes have been conclusively correlated with the CaP
initiation or progression, and this raises the question of how
to bypass the unavoidable contamination of 'tumour biop-
sies' by presumed non-malignant cells (for recent reviews see
Buttyan et al., 1993; Lisitsyn et al., 1993).
The gene encoding the tumour-suppressor protein TP53 is
the most frequently affected gene in human cancer, where
loss of both alleles has been observed, once through deletion,
the other through point mutation (Levine et al., 1991).
Studies of TP53 mutations in prostate cancer tissues have
demonstrated its potential as a marker in primary cancer, but
the different studies show a frequency ranging from 5-25%
of tumours bearing potential TP53 mutations (Isaacs et al.,
1991; Effert et al., 1992, 1993; Bookstein et al., 1993; Navone
et al., 1993; Uchida et al., 1993; Dinjens et al., 1994; Voeller
et al., 1994). By using an immunohistochemical method,
several groups reported frequencies of abnormal TP53
accumulation in 6-79% of the prostate cancer samples
(Soini et al., 1992; Visakorpi et al., 1992; Zhang et al., 1992;
Van Veldhuizen et al., 1993). In contrast, the occurrence of
TP53 mutations in benign prostatic hyperplasia has also been
reported, suggesting that these alterations may happen early
in the progression of prostate cancer (Meyers et al., 1993).
These contradictory results prompted us to develop a precise
approach to detect potentially 'hidden' mutations. We des-
cribe a molecular analysis technique using microdissection of
isolated and graded tumour cells before PCR amplification
of DNA and subsequent analysis using SSCP and DNA
sequencing.
Materials and methods
Selection, microdissection and DNA extractionfrom prostate
cancer cells
Using histological grading (Gleason, 1992) and cytological
features, foci of tumour cells were selected from frozen
8-10 lim sections of prostate tissue stained with
haematoxylin/eosin from two patients with prostate cancer
and undergoing radical prostatectomy. Microdissection was
carried out under light microscopy with a three-dimensional
micromanipulator (MO-188M/MN-188, Narishige, Nikon)
mounted on an inverted frame microscope (Diaphot TMD,
Nikon) to allow easy access to the sample. A sterile pulled
microcapillary was cut to render it sharp and strong enough
to resist bending and/or breaking (original diameter 1 mm,
Clark Electromedical Instruments, UK). After careful rehyd-
ration of the tissue with 10tl1 of sterile distilled water at
room temperature for 1 min, dissection of 20-100 cells of the
selected area was possible. The cells were removed by capil-
lary aspiration using a microinjector (IM-188, Narishige,
Nikon), and resuspended into 50 "l of sterile distilled water.
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1995DNA extraction was carried out by boiling the sample for
15 min in the presence of 250 mgml-' chelating resin
(iminodiacetic acid, 50-100 mesh, Sigma), 1 mM sodium hyd-
roxide in a final volume of 100fil covered by one drop of
mineral oil (after Singer-Sam et al., 1989). After centrifuga-
tion at 15000g for 5 min, the DNA solution was processed
for PCR.
PCR ofthe exons 5/6 ofthe TP53 gene
Oligonucleotide primers were selected to the target TP53
sequences using the Primer Designer Program (Scientific and
Educational Software, PA, USA) at bp 13 030 for the sense
primer (5'-CTCTGTCTCCTTCTTCTTCC-3') and bp 13 437
for the anti-sense primer (5'-CAGACCTCAGGCGGCTC-
ATA-3'), amplifying a product of407 bp covering both exons
5 and 6, and including the 90 bp intronic segment. The
primers were synthesised in a DNA synthesiser (PCR-Mate,
Applied Biosystems, model 391) and subsequently purified,
based on trityl group affinity. The PCR reaction mixture
contained 10 mM Tris-HCI pH 8.8, 50 mM potassium chloride
1.5 mM magnesium chloride, 200iLM each of dATP, dGTP,
dTTP and dCTP, and 2.6tLM of each 20 base primer. A
master mix containing all the above components and 2.5 U/
reaction of Taq polymerase (Taq XL, Northumbria
Biologicals, UK) was prepared. The reaction was initiated by
adding 10 ll of the sample DNA (150 pg DNA) to 40ftl of
the master mix, overlaid with one drop of mineral oil. The
tubes were transferred to a Perkin Elmer Cetus thermocycler
and treated as follows: 94°C for 4 min, then 40 cycles of
94°C, 55°C, 72°C of 1 min each, followed by a final extension
step of 72°C for 7 min. Positive and negative controls were
run in parallel to monitor the absence of contamination (an
important factor when using microdissected material). The
amplification products were separated by 1.5% agarose gel
electrophoresis, and the product size determined relative to a
100 bp ladder (Pharmacia).
SSCP analysis
Analysis was carried out essentially as described by Hayashi
(1991). The PCR products were labelled with [32P]-dATP (sp.
ac. 3000 Ci mmol ', Amersham) by Taq polymerase for 10
cycles under the same conditions as above. Samples for SSCP
were prepared for loading as follows: each sample was
adjusted to 80 000 c.p.m. in a final volume of 10ftl with
0.1% sodium dodecyl sulphate (SDS), 1OmM EDTA, mixed
with 15 tl of 95% formamide, 20 mM EDTA, 1% xylene
cyanol/bromphenol blue, heated at 70°C for 10 min and
finally chilled on ice before loading to the gel. The SSCP gels
were made up of 17% Hydrolink MDE (AT Biochem,
Malvern, PA, USA), 53 mM Tris-borate pH 8.3, 1.2 mM
sodium EDTA, 1.8 mM ammonium persulphate, 400 M
TEMED, using non-siliconised plates with 0.4 mm spacers.
After polymerisation, the wells were washed with 53 mM
Tris-borate pH 8.3, 1.2 mM sodium EDTA (running buffer),
samples loaded and the gels run for 7-8 h on 8 W constant
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power, then dried and exposed overnight at -80°C on
Hyperfilm MP (Amersham).
Construction ofTP53 insertional mutant
A PCR product corresponding to exons 5/6 of the normal
TP53 allele was prepared as described above, purified by
preparative gel electrophoresis and isolated by chromato-
graphy on DEAE paper. After extraction and purification,
the product was cloned directly in pT7Blue T-vector
(Novagen, Madison, WI, USA). The TP53 clone was then
linearised by Nco-l at position 13 155 of the TP53 gene,
which cut at a single site within the TPS3 insert and the
linearised plasmid DNA. The band was cut out of the gel
and purified using the Geneclean II kit (BIO 101, La Jolla,
CA, USA). The Nco-I site was then filled in using Klenow
polymerase and religated to produce a four base pair inser-
tion in the TP53 insert.
Results
To quantitatively determine the detection threshold for a
mutant TP53 allele in a background of normal alleles, we
mixed an insertion mutation of TP53 with its normal
counterpart at given ratios and submitted the mixture to
PCR amplification and SSCP analysis (Figure 1). The inser-
tion mutant was chosen for clarity of presentation, and
similar results were obtained with point mutations, which
form the majority of TPS3 mutants in vivo. In this system,
the mutated signal only appeared consistently at
mutant-normal allele ratios betwen 1:4 and 1:9 (and vice
versa for the normal allele in the presence of excess mutant).
Both alleles were amplified with approximately equal
efficiency in multiple experiments.
To reduce the contribution of normal alleles from non-
tumour tissue to the PCR amplification reaction, we have
developed a microdissection technique. As shown in Figure 2,
it was possible to take samples of well-documented cancer
foci and to process them for further analysis. Preliminary
experiments showed that using the primer set for TPS3 exons
5-8, it was possible to amplify genomic DNA from as little
as 36 pg (not shown). This amount of DNA represents the
content of three human cells. Furthermore, our aims were
not only to microdissect cancerous areas but also to obtain
normal stroma from the same biopsy section as an internal
control (Figure 2). By using this technique, we were able to
prepare enough DNA to carry out 10-20 PCR/SSCP
analyses from a single microdissection, which covers most of
the needs for the screening of one complete gene, although
different primer pairs may vary in their relative abilities to
amplify particular mutants. To illustrate the procedure, we
then analysed the state of the TP53 gene in two prostate
cancer specimens (9317 and 9318) which showed no reactivity
after immunoperoxidase staining and immunofluorescence
with monoclonal DO-1, which binds to the N-terminus of
denaturated stable TPS3 (Vojtesek et al., 1992), PAb 1620,
which is TP53 wild-type-specific (Ball et al., 1984; Milner et
al., 1987), PAb421, reacting with the C-terminus of TPS3
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Figure 1 SSCP dilution experiment with normal and mutated TP53 exons 5/6 PCR products. Gene amplification was carried out
by PCR with mixed wild-type DNA and the insertion mutant of TP53 exons 5/6 mixed in the ratios shown (see Materials and
methods). Analysis of the normal and mutated clones was carried out by SSCP. Normal and mutant profiles contain a common
band and a distinctive band associated with each TPS3 PCR product.Prostate cancer microdissection for molecular analysis
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Figure 2 Microdissection of selected human prostatic epithelial tumour cells and stroma in situ. Within the same frozen/fixed/
stained section, microdissection of selected areas representing the pathological features of prostate cancer (left, epithelium
microdissection) and the stromal cells considered to be normal (right, stroma microdissection) were performed using micropipettes
and micromanipulator (see Materials and methods). The different microdissection steps are shown x 400 (before, during, after) on
a section of a prostate cancer specimen scored 6 (3 + 3) according to Gleason grading. These selected microdissected foci were
located within an assigned grade 3 area. The (x 100) magnification photography shows both selected areas located in close
proximity, on the same section.Prostate cancer microdissection for molecularanalysis
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Figure 3 SSCP analysis ofprostate cancer specimens for TP53 exons 5/6 PCR products. PCR and SSCP analyses were carried out
with a crude DNA extract from fragment oftissue biopsy (top) but also DNA extracted from microdissected epithelial and stromal
areas (bottom) of carcinoma of the prostate (CaP) specimens 9317 and 9318 (see Materials and methods). While the profile of the
whole tissue biopsies did not show any changes from normal, the microdissected epithelial patterns revealed extra bands which were
subsequently analysed for presence of mutations. The epithelium band shifts for the CaP 9318 bands (1) and (2) were DNA
sequenced using a new method for specific determination of mutation in heterogeneous SSCP profile (Figure 4). The control for
TP53 is the normal counterpart clone of the TP53 insertional mutant constructed for the competition assay as shown in Figure 1.
The prostate cancer cell line PC-3 run in parallel possesses only one allele of TP53 carrying a nonsense mutation within the codon
138 of exon 5 (Isaacs et aL, 1991).
(Harlow et al., 1981) and PAb 240, which recognises a
hidden amino acid motif in wild-type TP53 (Gannon et al.,
1990; data not shown). Histopathologically, these tissues
were reported with a Gleason score of 6 (3 + 3), and in each
sample, a grade 3 tumour focus was selected and mic-
rodissected (Figure 2). In parallel, microdissection of an area
of the surrounding stroma was carried out. A DNA prepara-
tion from the total biopsy was also processed for TP53
mutations.
As shown in Figure 3, SSCP analysis of the PCR product
obtained from the gross DNA extraction of prostate car-
cinoma tissues 9317 and 9318, only revealed a band pattern
corresponding to normal TP53 alleles. On the other hand,
from the microdissected areas, the SSCP gel showed extra
bands for the epithelial cells, which were absent in the
stroma. Apart from the appearance of extra bands, the nor-
mal TP53 pattern was also present in the microdissected
epithelium 9317 and 9318, which may suggest either a
residual heterogeneity of the cell area taken, or perhaps that
the tumour cells contain one normal and one mutant TP53
copy. We consistently found in these experiments that the
strength of the PCR signal from the 'normal allele' was
greater than that from the mutant. By comparison, the pros-
tate cancer cell line PC-3, showed a completely different band
shift compared with the normal control (Figure 3). This cell
line has been shown to contain only one allele of TP53, with
a nonsense mutation at codon 138 (Isaacs et al., 1991).
To determine if an observed band shift for TP53 exons 5/6
is indicative of a mutation, the normal and abnormal bands
were extracted from the SSCP gel and directly sequenced
after a second amplification by PCR. In Figure 3 using the
specimen 9318, the SSCP bands labelled 1 and 2 were
checked for mutations. While band 1 did not show any
abnormality within the sequence, a point mutation was
revealed in band 2, considered as abnormal by comparison
with the normal migration pattern of TP53 exons 5/6 in
SSCP. Other minor species, when reamplified and sequenced,
were wild type, and presumably represent alternative minor
conformations adopted in the SSCP gel. The mutation was
detected at position 13 336 of the TP53 gene, and results in a
missense mutation glutamine+histidine at codon 192 within
exon 6 of the TP53 protein (Figure 4).
The DNA processed to obtain the data reported above was
prepared from freshly fixed and haematoylin-eosin-stained
frozen sections. We have also successfully extracted well-
conserved DNA, for the purpose of PCR/SSCP analysis,
from sections which have been previously immunostained
using standard avidin-biotin-peroxidase detection, counters-
tained with haematoxylin, mounted under commercially
available aqueous mounting media and then demounted for
final processing. These sections had been stored at room
temperature for up to 6 months. Furthermore, formalin-fixed
and paraffin-embedded sections also produced similar results
to freshly frozen/fixed sections, although it is clear that
freshly fixed tissues give superior results, particularly for the
amplification of DNA fragments greater than 500bp (not
shown). DNA has also been recovered from 10-year-old
archival tissue, but we have no doubt it is possible to extract
DNA from much older stored tissues.
Discussion
The purpose ofthis study was to develop a reliable molecular
analysis using homogeneous cell populations selected from
prostatic carcinomas, to avoid masking of tumour-specific
genetic changes by normal and reactive cells within the
tumour specimens. Despite careful biopsy technique and
crude microdissections, it has been almost impossible to
obtain homogeneous prostatic carcinoma tissue, to determine
molecular events involved in tumour development and pro-
gression (Sarkar et al., 1993).
Tissue heterogeneity makes it difficult to assess how many
copies of an abnormal gene are present compared with the
number of normal copies. This heterogeneity raises questions
about the reliability of results obtained from whole tissue
DNA preparations, in which the signal from mutant alleles
may be masked by the presence of normal alleles, and the
results of the reconstruction experiment (Figure 1) emphasise
the fact that at least 20% ofthe DNA present in the prepara-
tion before PCR should be mutated in order to score
positively in PCR/SSCP analysis. Since Bartsch et al. (1989)
could find only an average of 23% of tumour cells within 50
dissected biopsies of prostate cancer, our results suggest that
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Figure 4 Direct sequencing of specific DNA strands after SSCP separation of mutant and normal alleles. (a) Agarose gel (1.5%
GTG agarose) to separate the primary 407 bp PCR product generated from microdissected stromal and epithelial components of
prostatic carcinoma. (b) Autoradiograph (16 h exposure) of SSCP in a 17% MDE gel to separate the normal and mutant alleles of
TP53. Note that in the epithelial cells one of the mutant strands co-migrated with normal TP53 band 1. Fragment 2 was therefore
a putative mutant strand with altered mobility. (c) Confirmatory sequence analysis of purified band 1 from the (normal) stromal
track on the SSCP gel and band 2 from the epithelial track. Note that direct sequencing of band 1 from the epithelial track did not
give a mutant pattern on reamplification (data not shown), whereas a mutation was revealed in band 2 with an exon 6 point
mutation at position 13 336 (G T).
most genetic alterations in prostate cancer might escape
detection by standard molecular methods such as PCR/
SSCP. Furthermore, when only one allele is carrying a muta-
tion, as is often the case with p53, more than 40% of the
cells present in the specimen used for DNA extraction must
be from the tumour.
By developing a precise microdissection technique, we are
therefore able to analyse archival biopsies from patients who
initially present with benign prostatic disorders which may
progress to malignancy. However, with increased precision,
there is also the possibility of intra- and inter-sample cross
contamination, which can be ignored in most larger scale
analyses of human genes by PCR. Experience in the detection
of latent viral infections (Maitland and Lynas, 1991), and
minimal residual disease in leukaemia patients (Potter et al.,
1992) underlines this concern. We have taken every
reasonable precaution to avoid contamination, including UV
treatment by cryosectioning blades, individual sterile slides,
sterile microneedles discarded after each microdissection, and
individual PCR quality reagents used in dedicated class 2
facilities. We are therefore confident that the presence of a
strong normal TP53 allele signal in the SSCP analysis of
dissected tumour tissues is not a result of cross-
contamination. It could either be due to increased efficiency
of amplification of the normal allele, or to the presence of
normal cells, which are identical to. the tumour cells by both
histological and immunocytochemical analysis, within the
microdissected mass. Despite its frequent involvement in
human cancer, the existence of TP53 mutation in prostate
cancer remains unclear. Our experiments set out to study the
feasibility of SSCP band shift as a method of measuring the
frequency ofmutation in the human TP53 gene exons 5/6, by
PCR/SSCP analysis of microdissected prostate tissues con-
taining histopathologically documented tumour foci. We
chose these exons for a preliminary study since they are
frequently mutated in human cancer. According to Caron de
Fromentel and Soussi (1992), exons 5 and 6 contain respec-
tively, 28.5% and 12% of all p53 mutations, irrespective of
the origin of the tumour.
Careful studies of documented tumour after microdissec-
tion should increase the observed frequency of many muta-
tions, especially in prostate cancer when DNA abnormalities
could neither be detected by crude DNA preparation and/or
immunology. Our results emphasise the need for precise mic-
rodissection as part of a study of mutations in exons 5-8 of
TP53 where almost 97% mutations have been located in
human cancer (Cariello et al., 1994; Greenblatt et al., 1994;
Hollstein et al., 1994). It should also remove the uncertain
and inconsistent results obtained in many of the current
mutation studies with this tumour and other histologically
heterogeneous tumours (Noguchi et al., 1992; Whetsell et al.,
1992). Such studies are of critical importance to establish the
regulatory pathways which control stepwise progression
leading to prostatic carcinoma.
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